Retifanlimab for Brain Tumor
This trial will test a combination of drugs and radiation therapy to treat glioblastoma. The investigators hope that this will produce a more robust anti-tumor immune response and improve overall survival.
- Brain Tumor
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has Retifanlimab achieved governmental approval from the FDA?
"Our team has assessed the safety of Retifanlimab at a 2, as there's evidence to suggest it is safe but no data yet showing its efficacy."
Are there numerous places in the city that have started this experiment?
"At present, there are 4 sites operating for this research. These include Winston-Salem, Phoenix and Rochester as well as another undisclosed location. It is beneficial to pick the closest site in order to minimise your need to travel if you decide to join the study."
How many participants has this clinical trial incorporated thus far?
"48 suitable patients are needed to partake in this clinical trial. These individuals can be recruited from multiple locations, including Wake Forest Baptist Medical Center and Mayo Clinic in Phoenix."
To what conditions is Retifanlimab regularly employed for therapeutic purposes?
"Retifanlimab is a viable therapeutic option for patients suffering from recurrent platinum-sensitive primary peritoneal cancer, stage IV epithelial ovarian cancer after initial resection, and malignant neoplasms."
What other experiments have focused on Retifanlimab thus far?
"Presently, a total of 367 clinical trials are looking into the efficacy and safety of Retifanlimab. Of these experiments, 91 have advanced to Phase 3. While most research on this medication is conducted in Taibei, Taiwan, there are 17379 other sites around the world administering Retifanlimab studies."
Are there any vacancies remaining in this trial?
"According to information posted on clinicaltrials.gov, this medical trial is presently seeking participants. It was initially made available for recruitment on April 20th 2020 and its details were last updated in October 13th 2022."